Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smaller incision, faster recovery? new trial tests heart bypass techniques

NCT ID NCT03447938

Symptom relief Sponsor: Ottawa Heart Institute Research Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two types of heart bypass surgery for people with blocked arteries: a minimally invasive approach using small incisions between the ribs versus the traditional method that opens the breastbone. Researchers want to see if the less invasive surgery leads to better physical function and quality of life one month after the operation. About 176 patients are taking part, and they will be followed for a year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
minimally invasive coronary artery bypass grafting (MICS CABG) procedure
What this could lead to
If successful, this could show that a less invasive heart bypass surgery leads to faster recovery and better quality of life than the standard open-chest approach.
What could go wrong
This is a relatively small trial (176 patients) and results may not apply to all patients. The minimally invasive procedure is technically demanding and may not be suitable for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 176 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2018

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years of age or older * Angiographically-confirmed multi-vessel coronary artery disease lesions with \>=70% in at least 2 major epicardial vessels in 2 or more coronary artery territories (left anterior descending (LAD), circumflex (CX) and right coronary artery (RCA)) OR lesions \>=50% in the left main (LM) * Patients who, in the opinion of the investigator, are amenable for coronary surgery through either median sternotomy or minimally-invasive approach. * Patients who are willing and able to comply with all follow-up study visits. Exclusion Criteria: * \<18 years of age * concomitant cardiac procedure with CABG (e.g. valve repair or replacement) * Previous cardiac surgery, mediastinal irradiation, or significant trauma to the chest * Contra-indications for MICS CABG, including: severe pectus excavatum; severe pulmonary disease; hemodynamically significant left subclavian stenosis; morbid obesity; severe left ventricular (LV) dysfunction; no adequate PDA or marginal branch target; absence of femoral pulse bilaterally. * Contraindications for conventional CABG via sternotomy * Concomitant life-threatening disease likely to limit life expectancy to \<2 years * Emergency CABG with hemodynamic compromise * Inability to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease

Contacts and locations

Locations

  • Apollo Hospital, Bangalore

    Bangalore, Karnataka, 560041, India

  • Division of Cardiac Surgery, University of Ottawa Heart Institute

    Ottawa, Ontario, K1Y 4W7, Canada

  • Far-Eastern Memorial Hospital

    Taipei, Taipei, 220, Taiwan

  • Gundersen Lutheran Medical Center

    La Crosse, Wisconsin, 54601, United States

  • Jilin Heart Hospital

    Jilin City, Jilin, 130117, China

  • Leipzig Heart Institute GmbH

    Leipzig, Saxony, Germany

  • Manipal Hospitals

    New Delhi, National Capital Territory of Delhi, India

  • National University Hospital (NUH) - Singapore

    Singapore, Singapore

  • Robert-Bosch-Hospital

    Stuttgart, Germany

  • Tokyo Bay Urayasu Ichikawa Medical Center

    Urayasu, Chiba, Japan

  • Universitaire Ziekenhuizen Leuven

    Leuven, Belgium

  • University Health Network

    Toronto, Ontario, Canada

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.